Argenx Se: Strong Growth Prospects and Attractive Buying Opportunity Amid Vyvgart Expansion and Upcoming Catalysts

Samantha Semenkow, an analyst from Citi, reiterated the Buy rating on Argenx Se (ARGX – Research Report). The associated price target remains the same with $803.00.

Samantha Semenkow’s rating is based on the belief that the growth trajectory for Argenx Se remains strong, despite concerns about the launch of Vyvgart. The recent decline in stock price presents an attractive buying opportunity, as shares have not yet returned to their previous highs. Semenkow anticipates continued growth for Vyvgart, bolstered by recent approvals and the expansion of its launch into new areas.
Furthermore, the potential for label expansion into additional indications such as seronegative generalized myasthenia gravis (gMG) and ocular MG is expected to sustain growth and provide low-risk opportunities for the company’s pipeline. Beyond gMG, upcoming data releases in the second half of 2025 and 2026, including those for lupus nephritis, myositis, TED, and MMN, are seen as potential catalysts for further commercial expansion. These factors contribute to a favorable risk/reward profile, leading to the reiteration of a Buy rating with an expected share price return of 38.9%.

Semenkow covers the Healthcare sector, focusing on stocks such as Argenx Se, Catalyst Pharma, and Larimar Therapeutics. According to TipRanks, Semenkow has an average return of -23.1% and a 22.83% success rate on recommended stocks.

In another report released on May 15, H.C. Wainwright also maintained a Buy rating on the stock with a $720.00 price target.